Project Grant HT94252410452
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$300K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
The federal Project Grant award, valued at $1,944,610.00 and effective from April 1, 2025 to March 31, 2028, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The primary awardee, Sloan-Kettering Institute for Cancer Research, will conduct research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. This work will involve collaboration with The University of Texas MD Anderson Cancer...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
This federal Project Grant award, valued at $1,477,615.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. The University of British Columbia, through its Research Services division, is the awardee and will conduct this advanced biomedical research project over a...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award of $1,120,707 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research conducted by the University of Queensland in Australia. The research aims to develop a first-in-class calcium channel inhibitor for the treatment of advanced metastatic prostate cancers resistant to next-generation antiandrogen therapy. The award has a performance period from July 1, 2025 to June 30, 2028. The...
The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports...
This Project Grant from the Defense Health Agency provides $494,811 to the University of Cambridge under the Military Medical Research and Development program (CFDA 12.420) from April 1, 2023 to March 31, 2026. The grant funds research to elucidate and target clonal lineages influencing resistance to therapy in distinct mutational subtypes of high-grade ovarian serous carcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...